Widening the PDE-10 landscape
elbion N.V. was to announce on Monday this week that it will co-develop its discovery stage phosphodiesterase-10 inhibitors for schizophrenia and other CNS disorders with Wyeth. The deal adds WYE to a handful of pharma companies that have disclosed work on PDE-10 inhibitors. It also will provide resources for elbion to advance its internal and newly acquired products.
The companies will